Literature DB >> 18652554

Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.

Blanca I Restrepo1, Susan P Fisher-Hoch, Paula A Pino, Adrian Salinas, Mohammad H Rahbar, Francisco Mora, Nicolas Cortes-Penfield, Joseph B McCormick.   

Abstract

BACKGROUND: Although the biological basis for the increased susceptibility of diabetic patients to tuberculosis remains unclear, the world is undergoing a type 2 diabetes pandemic. We hypothesize that chronic hyperglycemia leads to immunocompromise that facilitates progression to active tuberculosis. To assess this possibility, we determined whether patients with tuberculosis and diabetes (particularly those with chronic hyperglycemia), compared with patients with tuberculosis who did not have diabetes, presented altered cytokine responses to a mycobacterial antigen.
METHODS: Samples of whole blood from patients with tuberculosis and diabetes and from patients with tuberculosis who did not have diabetes was stimulated in vitro with purified protein derivative from Mycobacterium tuberculosis. We then determined whether there was an association between the levels of innate and adaptive cytokines secreted in response to the antigen and diabetes status, or diabetes with chronic hyperglycemia (measured by glycosylated hemoglobin level), after controlling for possible confounders.
RESULTS: Innate and type 1 cytokine responses were significantly higher in patients with tuberculosis who had diabetes than in nondiabetic control subjects. The effect was consistently and significantly more marked in diabetic patients with chronic hyperglycemia.
CONCLUSIONS: These data provide preliminary evidence that type 2 diabetes, especially type 2 diabetes involving chronic hyperglycemia, is associated with an altered immune response to M. tuberculosis. More-detailed knowledge of the underlying mechanisms should focus on the effect of chronic hyperglycemia on the immune response to help in understanding the enhanced susceptibility of diabetic patients to tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652554      PMCID: PMC2900313          DOI: 10.1086/590565

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  38 in total

1.  Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances.

Authors:  Blanca I Restrepo
Journal:  Clin Infect Dis       Date:  2007-07-05       Impact factor: 9.079

2.  Changes in phagocytic function with glycaemic control in diabetic patients.

Authors:  S M MacRury; C G Gemmell; K R Paterson; A C MacCuish
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

3.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; David E Bruns; David E Goldstein; Noel K Maclaren; Jay M McDonald; Marian Parrott
Journal:  Clin Chem       Date:  2002-03       Impact factor: 8.327

4.  Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology.

Authors:  L Llorente; H De La Fuente; Y Richaud-Patin; C Alvarado-De La Barrera; A Diaz-Borjón; A López-Ponce; I Lerman-Garber; J Jakez-Ocampo
Journal:  Immunol Lett       Date:  2000-11-01       Impact factor: 3.685

Review 5.  Is type II diabetes mellitus a disease of the innate immune system?

Authors:  J C Pickup; M A Crook
Journal:  Diabetologia       Date:  1998-10       Impact factor: 10.122

6.  Defective HLA class II expression in monocytes of type 1 diabetic patients. The Childhood Diabetes in Finland Study Group.

Authors:  P Parkkonen; H Hyöty; T Huupponen; P Leinikki; E Tuomilehto-Wolf; M Knip
Journal:  APMIS       Date:  1993-05       Impact factor: 3.205

Review 7.  Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response.

Authors:  Volker Briken; Steven A Porcelli; Gurdyal S Besra; Laurent Kremer
Journal:  Mol Microbiol       Date:  2004-07       Impact factor: 3.501

8.  HLA class II antigens and interleukin-1 in patients affected by type-II diabetes mellitus and hyperlipemia.

Authors:  C Romano-Carratelli; M Galdiero; C Bentivoglio; I Nuzzo; D Cozzolino; R Torella
Journal:  J Med       Date:  1993

9.  Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice.

Authors:  Radia Tamarat; Jean-Sébastien Silvestre; Maya Huijberts; Joelle Benessiano; Teni G Ebrahimian; Micheline Duriez; Marie-Paule Wautier; Jean Luc Wautier; Bernard I Lévy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-12       Impact factor: 12.779

Review 10.  Host innate immune response to Mycobacterium tuberculosis.

Authors:  Kamlesh Bhatt; Padmini Salgame
Journal:  J Clin Immunol       Date:  2007-03-16       Impact factor: 8.542

View more
  76 in total

1.  Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis.

Authors:  Nathella P Kumar; Rathinam Sridhar; Dina Nair; Vaithilingam V Banurekha; Thomas B Nutman; Subash Babu
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  Diabetes and Tuberculosis.

Authors:  Blanca I Restrepo
Journal:  Microbiol Spectr       Date:  2016-12

Review 3.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

4.  Heightened plasma levels of heme oxygenase-1 and tissue inhibitor of metalloproteinase-4 as well as elevated peripheral neutrophil counts are associated with TB-diabetes comorbidity.

Authors:  Bruno B Andrade; Nathella Pavan Kumar; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Thomas B Nutman; Alan Sher; Subash Babu
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

Review 5.  Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections.

Authors:  Kelly Hodgson; Jodie Morris; Tahnee Bridson; Brenda Govan; Catherine Rush; Natkunam Ketheesan
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

6.  Prevalence and Impact of Diabetes Mellitus Among Patients with Active Pulmonary Tuberculosis in South Korea.

Authors:  Eun Hye Lee; Jung Mo Lee; Young Ae Kang; Ah Young Leem; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Song Yee Kim
Journal:  Lung       Date:  2017-02-09       Impact factor: 2.584

7.  Impaired Cytokine but Enhanced Cytotoxic Marker Expression in Mycobacterium tuberculosis-Induced CD8+ T Cells in Individuals With Type 2 Diabetes and Latent Mycobacterium tuberculosis Infection.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Parakkal Jovvian George; Chandrakumar Dolla; Paul Kumaran; Subash Babu
Journal:  J Infect Dis       Date:  2015-10-20       Impact factor: 5.226

Review 8.  Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms.

Authors:  Katharina Ronacher; Reinout van Crevel; Julia A Critchley; Andrew A Bremer; Larry S Schlesinger; Anil Kapur; Randall Basaraba; Hardy Kornfeld; Blanca I Restrepo
Journal:  Chest       Date:  2017-04-20       Impact factor: 9.410

9.  Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus.

Authors:  Nathella Pavan Kumar; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Thomas B Nutman; Subash Babu
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

Review 10.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.